Portal de Periódicos da CAPES

Anti-inflammatory Disease Therapies

2012; SAGE Publishing; Volume: 40; Issue: 1 Linguagem: Inglês

10.1177/0192623311425064

1533-1601

Sarah Bolton, Dave Hassall, Deon Hildebrand, Wolfgang Brück, Jeffrey K. Huang, Stefano Pluchino, Tom P. McKevitt, Joel D. Parry, Mary McFarlane, Rajni Fagg, Aude Roulois,

Cancer Research and Treatment

Abbreviations: ASC, adult stem cell line; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; MS, multiple sclerosis; MSC, mesenchymal stem cell; NPCs, neural stem/precursor cells; OPCs, oligodendrocyte precursor cells; RNA, ribonucleic acid; RXR, retinoic X receptor; siRNA, small interference RNA. 122 BSTP Annual Scientific Meeting Abstracts Toxicologic Pathology, 40: 122-125, 2012 Copyright # 2012 by The Author(s) ISSN: 0192-6233 print / 1533-1601 online DOI: 10.1177/0192623311425064 properties early on in the discovery phase as well as the pharmacology of human cell systems and human lung tissues. Generating pharmacokinetics, toxicokinetics, and pharmacokinetics/pharmacodynamics in preclinical species to aid clinical dose prediction by the inhaled route is also important. Depending on the final molecular characteristics, the drug can be administered either via nebulization or by dry-powder devices. Advances in dry-powder technology suggest future potential targeted delivery to central or peripheral locations in the patient lung. This, coupled with a better understanding of inflammatory disease endpoints, should provide greater confidence in delivering the right dose to the right location and the use of a broader assessment of clinical efficacy to demonstrate a clear clinical benefit. It is only when all of these challenges are overcome that we will be able to affect the underlying disease directly and thereby decrease overall morbidity and mortality. DEVELOPING THERAPIES FOR INFLAMMATORY DISEASES: INHALED